[1] Akasaka Y, Nakajima T, Koyama K, et al. Familial cases of a new systemic bone disease, hereditary gnatho-diaphyseal sclerosis [J]. Nihon Seikeigeka Gakkai Zasshi, 1969, 43(5): 381-394.
[2] Riminucci M, Collins MT, Corsi A, et al. Gnathodiaphyseal dysplasia: a syndrome of fibro-osseous lesions of jawbones, bone fragility, and long bone bowing[J]. J Bone Mineral Res, 2001, 16(9): 1710-1718.
[3] Li X, Wang L, Wang HW, et al. Ano5 modulates calcium signaling during bone homeostasis in gnathodiaphyseal dysplasia [J]. NPJ Genom Med, 2022, 7(1):48-51.
[4] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126(4): 663-676.
[5] Deyle DR, Khan IF, Ren G, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs [J]. Mol Ther, 2012, 20(1): 204-213.
[6] Kao CL, Tai LK, Chiou SH, et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells [J]. Stem Cells Dev, 2010, 19(2): 247-258.
[7] Nasu A, Ikeya M, Yamamoto T, et al. Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin[J]. PLoS One, 2013, 8(1): e53771.
[8] Okamoto H, Matsumi Y, Hoshikawa Y, et al. Involvement of microRNAs in regulation of osteoblastic differentiation in mouse induced pluripotent stem cells [J]. PLoS One, 2012, 7(8): e43800.
[9] Jang Y, Choi J, Park N, et al. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering [J]. Exp Mol Med, 2019, 51(1): 1-11.
[10] Lee G, Ramirez CN, Kim H, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression [J]. Nat Biotechnol, 2012, 30(12): 1244-1248.
[11] Takeda R, Yasui T, Kasai T, et al. Surgical treatment of pathological tibial shaft fracture in adult patient with gnathodiaphyseal dysplasia: a case report [J]. JBJS Case Connect, 2021, 11(2): e21.00005.
[12] Otaify GA, Whyte MP, Gottesman GS, et al. Gnathodiaphyseal dysplasia: severe atypical presentation with novel heterozygous mutation of the anoctamin gene(ANO5)[J]. Bone, 2018, 107(1): 161-171.
[13] Pedemonte N, Galietta LJ. Structure and function of TMEM16 proteins (anoctamins) [J]. Physiol Rev, 2014, 94(2): 419-459.
[14] Jin L, Liu Y, Sun F,et al. Three novel ANO5 missense mutations in Caucasian and Chinese families and sporadic cases with gnathodiaphyseal dysplasia [J]. Sci Rep, 2017, 7: 40935.
[15] Tsutsumi S, Kamata N, Vokes TJ, et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD) [J]. Am J Hum Genet, 2004, 74(6): 1255-1261.
[16] Li HY, Wang XY, Chen EJ, et al. Introduction of a Cys360Tyr mutation in ANO5 creates a mouse model for gnathodiaphyseal dysplasia [J]. J Bone Mineral Res, 2022, 37(3): 515-530.
[17] Rolvien T, Avci O, Von kroge S, et al. Gnathodiaphyseal dysplasia is not recapitulated in a respective mouse model carrying a mutation of the Ano5 gene [J]. Bone Rep, 2020, 12:100281.
[18] Wang XY, Liu X, Dong R, et al. Genetic disruption of anoctamin 5 in mice replicates human gnathodiaphyseal dysplasia (GDD) [J]. Calcif Tissue Int, 2019, 104(6): 679-689.
[19] Di Zanni E, Gradogna A, Picco C, et al. TMEM16E/ANO5 mutations related to bone dysplasia or muscular dystrophy cause opposite effects on lipid scrambling[J]. Hum Mutat, 2020, 41(6): 1157-1170.
[20] Di Zanni E, Gradogna A, Scholz-starke J, et al. Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia [J]. Cell Mol Life Sci, 2018, 75(9): 1657-1670.
[21] Choi J, Lee S, Mallard W, et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs [J]. Nat Biotechnol, 2015, 33(11): 1173-1181.
[22] Guan J, Wang G, Wang J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells [J]. Nature, 2022, 605(7909): 325-331. |